The European Commission has opened an antitrust investigation into Sanofi over concerns that its flu vaccine campaign may have restricted competition in the market.
The probe will examine whether Sanofi engaged in practices that could have limited fair access for rival vaccine manufacturers, potentially influencing how flu vaccines are promoted and distributed across the European Union.
At the center of the investigation is whether the company’s campaign strategy created barriers for competitors, particularly during critical vaccination periods when demand is high and market access is essential.
Antitrust regulators are increasingly scrutinizing pharmaceutical companies, especially in areas where public health and market dynamics intersect. The outcome of this case could have broader implications for how vaccine campaigns are structured and regulated across the region.
This investigation will assess whether market practices have undermined fair competition in the vaccine sector.
Regulatory source — as reported by Reuters, June 26, 2026
If the European Commission finds evidence of anti-competitive behavior, Sanofi could face significant penalties and be required to adjust its market practices.
The case adds to a growing wave of regulatory actions targeting large pharmaceutical firms, as authorities push to ensure transparency, fairness, and equal market access in critical healthcare sectors.